Zalunfiban
As of the edition of 20 October 2026, Zalunfiban is a small molecule: of no established status; acts on ITGA2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITGA2B | Integrin alpha-IIb | P08514 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CeleCor Therapeutics | Lead sponsor of trials | 2021 to now |